Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

When breast cancer patients start to exhibit resistance to hormonal therapy or chemotherapy, the mTOR inhibitor everolimus can be considered as an alternative therapeutic agent. Everolimus can deregulate the PI3K/AKT/mTOR pathway and affect a range of cellular functions. In some patients, the agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Chun-Ting, Chen, Chen-Lin, Li, Chih-Chi, Huang, Guan-Syuan, Ma, Wei-Yuan, Hsu, Wei-Fan, Lin, Ching-Hung, Lu, Yen-Shen, Wo, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662705/
https://www.ncbi.nlm.nih.gov/pubmed/31358767
http://dx.doi.org/10.1038/s41598-019-45319-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662705/
https://www.ncbi.nlm.nih.gov/pubmed/31358767
http://dx.doi.org/10.1038/s41598-019-45319-4

Ejemplares similares